Cargando…
The adoption of nintedanib in systemic sclerosis: the SENSCIS study
Nintedanib shows a statistically significant effect on lung function decay in patients with ILD secondary to systemic sclerosis, but no effect on skin fibrosis and on health-related quality of life http://bit.ly/2vfJRj7
Autores principales: | Bruni, Teresa, Varone, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341613/ https://www.ncbi.nlm.nih.gov/pubmed/32665787 http://dx.doi.org/10.1183/20734735.0005-2020 |
Ejemplares similares
-
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022) -
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020) -
Review of the clinical evidence for interferon β 1a (Rebif(®)) in the treatment of multiple sclerosis
por: Manfredonia, Francesco, et al.
Publicado: (2008) -
Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007) -
Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial
por: Volkmann, Elizabeth R, et al.
Publicado: (2022)